Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease‐based registry (PSOLAR)3. (16th July 2014)

• Record Type: Journal Article
• Authors: Kimball, A.B.; Leonardi, C.; Stahle, M.; Gulliver, W.; Chevrier, M.; Fakharzadeh, S.; Goyal, K.; Calabro, S.; Langholff, W.; Menter, A.; the PSOLAR Steering Committee
• Is Part Of: British journal of dermatology. Volume 171:Number 1(2014:Jul.)
• Page Start: 137
• Page End: 147
• Publication Date: 2014-07-16
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.13013
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="main" id="bjd13013-abs-0001"> <title>Summary</title> <sec id="bjd13013-sec-0001" sec-type="section"> <title>Background</title> <p>Psoriasis is associated with several comorbidities and behavioural risk factors.</p> </sec> <sec id="bjd13013-sec-0002" sec-type="section"> <title>Objectives</title> <p>To evaluate demographic and disease characteristics in patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).</p> </sec> <sec id="bjd13013-sec-0003" sec-type="section"> <title>Methods</title> <p>PSOLAR is a global, prospective, longitudinal, disease‐based registry that includes a postmarketing commitment to evaluate safety in patients with psoriasis. Enrolled patients had to be receiving, or be eligible to receive, conventional systemic or biological agents. Demographic/disease characteristics, medical histories, lifestyle risk factors and previous treatments are collected at enrolment. Efficacy and safety data are collected every 6 months for 8 years, and data are extracted annually. Selected parameters are evaluated by age quartile using post hoc analyses.</p> </sec> <sec id="bjd13013-sec-0004" sec-type="section"> <title>Results</title> <p>As of 23 August 2012, 11 900 patients were enrolled at 301 sites in North America, Europe and Latin America. Over half of the PSOLAR population (54·7%) is male, with a mean age of 48·6 years and mean body mass index of 30·9 kg m<sup>−2</sup> at enrolment. Mean duration of disease at enrolment was 17·5 years, and mean Physician's Global Assessment score was 2·0. Psoriatic arthritis (35·5%) and cardiovascular diseases (38·2%) were highly prevalent. Diabetes mellitus type II was reported in 11·4% of patients. Depression and anxiety were noted in 14·7% and 11·1% of patients, respectively; 79·0% reported any alcohol use and 56·7% reported smoking or a history of smoking. The occurrence of most comorbidities, including cardiovascular disease and risk factors, increased with age.</p> </sec> <sec id="bjd13013-sec-0005" sec-type="section"> <title>Conclusions</title> <p>In the PSOLAR population, multiple and age‐appropriate comorbidities are associated with psoriasis and may affect the selection of psoriasis treatments.</p> </sec> </abstract>